Amneal Pharmaceuticals Class A AMRX 深 沪
等待开盘 11-05 09:30:00 美东时间
11.35
+0.155
+1.38%
华盛通- 最 高11.40
- 今 开10.92
- 成交量 244.12万股
- 最 低 10.92
- 昨 收 11.195
- 总市值 35.64亿
- 52周最高 11.40
- 市盈率 静 --
- 换手率 0.78%
- 52周最低 6.685
- 委 比 -28.15%
- 总股本 3.14亿
- 历史最高 24.48
- 量 比 1.14
- 振 幅 4.29%
- 历史最低 1.24
- 每 手 1
- 风险率 0.92%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 苹果、亚马逊、Cloudflare、西部数据、Twilio等获十多家机构集体上调目标价；杰富瑞首予Cloudflare"持有"评级，目标价250美元
今日重点评级关注：康托·菲茨杰拉德：维持Cabaletta Bio"超配"评级，目标价从15美元升至30美元；HC Wainwright & Co.：维持Invivyd"买入"评级，目标价从5美元升至10美元
11-03 20:20
Earnings Scheduled For October 30, 2025
Companies Reporting Before The Bell • Altria Group (NYSE:MO) is projected to re...
10-30 19:12
Amneal Pharmaceuticals Raises FY2025 Adj EPS Guidance from $0.70-$0.75 to $0.75-$0.80 vs $0.77 Est; Affirms FY2025 Sales Guidance of $3.000B-$3.100B vs $3.011B Est
Amneal Pharmaceuticals (NASDAQ:AMRX) raises FY2025 Adj EPS guidance from $0.70-$0.75 to $0.75-$0.80 vs $0.77 analyst estimate. Affirms FY2025 sales outlook from $3.000 billion-$3.100 billion to $3.000 billion-$3.100
10-30 18:02
Amneal Launches Brekiya® – the First and Only DHE Autoinjector for Adults with Migraine With or Without Aura and Cluster Headaches
Amneal Pharmaceuticals launched Brekiya® autoinjector, the first and only ready-to-use dihydroergotamine (DHE) autoinjector for treating migraines and cluster headaches in adults. Available exclusively through Walgreens and Sterling Specialty Pharmacies, Brekiya offers patients a convenient alternative to emergency room visits. Migraines affect 43 million Americans, and cluster headaches impact 300,000 individuals, with limited treatment options ...
10-27 12:00
Trump administration prepares probe targeting global drug pricing — FT
The Trump administration is preparing to launch a new investigation under Section 301 of the Trade Act of 1974 to determine whether U.S. trading partners are underpaying for prescription drugs, potent...
10-22 17:26
Teva, Viatris On Investor Watch As White House Spares Generic Drugs From Tariffs
The Trump administration backs off plans to impose tariffs on generic drugs after internal debate over price impacts and supply concerns.
10-09 21:31
Amneal Pharma Submits BLA To FDA For Proposed Biosimilar To XOLAIR, Developed By Kashiv BioSciences
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) ("Amneal" or the "Company") today announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for a proposed biosimilar to XOLAIR® (omalizumab), developed by Kashiv BioSciences, LLC.
09-26 20:05
Amneal Announces BLA Submission of Biosimilar Candidate to XOLAIR® (omalizumab)
Amneal Pharmaceuticals submitted a Biologics License Application (BLA) for a biosimilar to XOLAIR (omalizumab) to the FDA, developed by Kashiv BioSciences. XOLAIR, with U.S. annual sales of approximately $4.1 billion, is used for treating moderate to severe asthma, chronic rhinosinusitis, food allergies, and chronic urticaria. Amneal expects this submission to be a key growth driver, targeting the large U.S. market and planning additional biosimi...
09-26 12:00
美股大行评级 | Arete Research上调百度"买入"评级，目标价143美元；瑞银上调蔚来"买入"评级，目标价升至8.5美元
今日重点评级关注：HC Wainwright & Co.：维持Orion Energy Sys"买入"评级，目标价从2美元升至20美元；高盛：维持Amylyx Pharmaceuticals"买入"评级，目标价从10美元升至20美元
09-17 10:15
JP Morgan Maintains Overweight on Amneal Pharmaceuticals, Raises Price Target to $14
JP Morgan analyst Chris Schott maintains Amneal Pharmaceuticals (NASDAQ:AMRX) with a Overweight and raises the price target from $12 to $14.
09-16 19:38
